From new product innovations to the automation of complex cell therapy and organoid workflows, we are excited to share our latest technologies with the life science community at SLAS.
SAN JOSE, CA (PRWEB)
February 03, 2022
Molecular Devices, LLC., a leading provider of high-performance solutions for the life sciences, and a Danaher Corporation (NYSE: DHR) company, will participate in a hybrid fashion at the Society for Laboratory Automation and Screening (SLAS) International Conference & Expo ) of this year, which will be held from February 5 to 9, 2022, in Boston, Massachusetts. Attendees can visit the company’s virtual booth to connect with on-demand subject matter experts or explore the latest advances in cell line development, 3D biology and drug screening through hands-on courses. short course, tutorials, poster presentations, etc.
“From new product innovations to the automation of complex cell therapy and organoid workflows, we are excited to share our latest technologies with the life sciences community at SLAS,” said Susan Murphy, President of Molecular Devices. “Our biopharma and 3D biology experts will be present in our virtual booth to demonstrate the technology and automated workflows that allow scientists to obtain new, reproducible research information while saving time and money.”
Presentation and virtual stand
Click on here for an overview of Molecular Devices’ hybrid presence at SLAS. Registered attendees can visit the virtual stand herewhere representatives will be available on demand to explore how the company’s life science solutions enable end-to-end automated workflows for cell line development, 3D biology and drug screening.
The recently launched CloneSelect® FL Imager (CSI FL) will be on virtual display with more details on this next-generation monoclonal verification imaging platform for automatic zero-day monoclonality assurance. The CSI FL offers high-speed imaging of banked cell lines with CRISPR-confirmed changes, helping to accelerate the therapeutic discovery process, while providing comprehensive audit trail regulatory reporting.
Short course and tutorials
Improve your 3D cell culture: from research to high throughput on Sunday, February 6, 2022. This short course will be co-led by scientists from Corning Life Sciences and Molecular Devices. It is designed to provide educational information and hands-on techniques that help participants move 3D applications from research-based manual labor to a more automated, mid- to high-throughput environment.
High-Throughput Phenotypic Screening with Organ-on-a-Chip: Future? Reality! on Monday, February 7, 2022. This tutorial delivered by MIMETAS and featuring Molecular Devices will demonstrate how organ-on-a-chip technology enables scientists to develop physiologically relevant disease models in a platform fully compatible with automated imaging and robotic manipulation for better drug development.
Emerging organoid models: translating basic research into drug development and regenerative medicine on Tuesday, February 8, 2022. The Center for Stem Cell and Organoid Medicine (CuSTOM) at Cincinnati Children’s Hospital Medical Center and Molecular Devices meet to discuss new advances in engineering next-generation organoids with complexity at the level of organs, relevant biomedical applications and how to overcome common challenges.
Automation-based 3D organoid culture workflow with deep learning-based label-free image analysis on Monday, February 7, 2022. Learn how Molecular Devices overcame common challenges in the process of culturing 3D cell models by developing an end-to-end workflow that uses deep learning automation and analytics tools for the growth, maintenance and monitoring of organoids in culture.
Intestinal organoids for automated screening tests; high-content imaging and analysis of organoid morphology on Tuesday, February 8, 2022. This poster highlights an organoid culture workflow leveraging a work cell that integrates automated imaging, incubator, liquid handler, and robotic technology, streamlining the process of seeding to compound testing and analysis.
Assessing Thrombin Generation with the TECHNOTHROMBIN TGA Kit on the SpectraMax i3x Multi-Mode Microplate Reader on Tuesday, February 8, 2022. Assessing the generation of thrombin in a plasma sample provides insight into the mechanisms of coagulation. This poster demonstrates an ideal platform to perform thrombin generation assays with good precision for research purposes.
Simplified, user-friendly and automated workflow for phenotypic profiling based on cell paint assay on Wednesday, February 9, 2022. Molecular Devices introduces a comprehensive, automated workflow for cell paint assay to address the typically time-consuming and laborious process. The team leveraged an automated liquid handler from Beckman Coulter Life Sciences and a machine learning-based data analysis platform from partner Core Life Analytics called StratoMineR™. StratoMineR is now offered by Molecular Devices, enabling customers to streamline and simplify the analysis of robust datasets from high-content screening experiments for actionable insights.
Automation of the organ-on-chip test: automated culture, imaging and analysis of angiogenesis on Wednesday, February 9, 2022. In this poster co-authored by scientists from MIMETAS and Beckman Coulter Life Sciences, Molecular Devices presents an automated workflow for on-chip organ cell culture, monitoring, and analysis to facilitate and expand the use of organ-on-a-chip systems.
To learn more about how Molecular Devices helps customers advance scientific discovery, visit http://www.moleculardevices.com.
About Molecular Devices, LLC.
Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. A broad product portfolio includes platforms for high-throughput screening, genomic and cell analysis, colony selection and microplate detection. These cutting-edge products enable scientists to improve productivity and efficiency, accelerating research and the discovery of new treatments. Molecular Devices is committed to continuously developing innovative solutions for life science applications. The company is headquartered in Silicon Valley, California, and has offices around the world.
Share the article on social networks or by e-mail: